Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925990 · ClinicalTrials.gov registry record · Phase 2
CTS-1027 in Interferon-Naive Hepatitis C Patients
A Phase 2 study, sponsored by Conatus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00925990 is a Phase 2 study that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT00925990, a Phase 2 study, has completed, sponsored by Conatus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.
Interventions
- DRUG ribavirin
- DRUG CTS-1027
- DRUG Placebo for ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925990
The ClinicalTrials.gov registry entry for NCT00925990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ribavirin is the first listed.
NCT00925990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925990 about?
NCT00925990 is a clinical study titled "CTS-1027 in Interferon-Naive Hepatitis C Patients". The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.
What is the current status of trial NCT00925990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2009-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00925990?
The interventions under investigation include: ribavirin (DRUG), CTS-1027 (DRUG), Placebo for ribavirin (DRUG).
Who is sponsoring clinical trial NCT00925990?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.